Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin CEO Will Now Focus on Strategic Matters and External Dialogue
May 1, 2025
- Japan Pharma Sales Creep Up to 10.8 Trillion in FY2024: Encise
May 1, 2025
- Paxlovid Filed for Pediatric Label Expansion in Japan: Pfizer
May 1, 2025
- Moderna Taps Asia Chief as Japan Representative Director, Marketing Head as GM
April 28, 2025
- Astellas Gears Up for Xtandi Patent Cliff with Next-Gen Assets, Cost Cuts
April 28, 2025
- Novo Nordisk Logs 3.6% Growth in Japan in 2024, Driven by Semaglutide
April 28, 2025
- Daiichi Sankyo Marks 2-Digit Growth in Sales, Net Profit Driven by Enhertu
April 28, 2025
- Rohto Kicks Off Japan PII for Regenerative Medicine for Heart Failure
April 28, 2025
- Sanofi’s Dupixent Filed for Bullous Pemphigoid in Japan
April 28, 2025
- Seikagaku, Ono to Tie Up on Osteoarthritis Drug in Japan
April 28, 2025
- BMS Oncology VP Goto to Lead Argenx Japan
April 25, 2025
- Gilead Files Trodelvy for HR+/HER2- Breast Cancer in Japan
April 25, 2025
- Enhertu Filed for HER2 Positive Solid Tumors in Japan
April 25, 2025
- Sanofi Looks to Join Top 3 in Japan Pharma Market by 2030
April 25, 2025
- Meiji’s Rezurock Grabs Approval in Taiwan
April 25, 2025
- Novo Unveils 4 Billion Yen Investment in Japan Factory
April 24, 2025
- Japan Approves Spikevax’s Prefilled Syringe Version
April 24, 2025
- Takeda’s Japan Earnings Bottomed Out, Now on Pace to Growth from FY2025: Head
April 23, 2025
- BeiGene Sees Better-than-Expected Uptake for Brukinsa after March Launch
April 23, 2025
- CSL to Join Forces with Specialists to Raise Awareness of HAE: Japan President
April 23, 2025
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…